Literature DB >> 11119510

Signaling via interleukin-4 receptor alpha chain is required for successful vaccination against schistosomiasis in BALB/c mice.

A P Mountford1, K G Hogg, P S Coulson, F Brombacher.   

Abstract

Although protective immunity in C57BL/6 mice induced by a single dose of the radiation-attenuated schistosome vaccine is believed to be mediated by Th1-type immune responses, we here report that in BALB/c mice protection can also depend upon signaling via the interleukin-4 (IL-4) receptor which conventionally governs the development of Th2-type immune responses. We show that in BALB/c mice deficient for the IL-4 receptor alpha chain (IL-4Ralpha(-/-)), which are unresponsive to IL-4 and IL-13, vaccine-induced protection is abrogated compared with that in wild-type (WT) mice. In vaccinated IL-4Ralpha(-/-) mice, IL-12p40 production by cells from the skin exposure site was elevated, although gamma interferon (IFN-gamma) production in draining lymphoid tissues was similar in WT and IL-4Ralpha(-/-) mice. Nevertheless, the effector response in IL-4Ralpha(-/-) mice was Th1 biased with elevated IFN-gamma in the lungs and higher immunoglobulin G2a (IgG2a) and IgG2b titers but negligible quantities of Th2-associated IgG1 and IgE. Interestingly, levels of IL-4 were equivalent in WT and IL-4Ralpha(-/-) mice, indicating that Th2 responses were not dependent upon signaling by IL-4 or IL-13. No differences in the phenotype and composition of the pulmonary effector mechanism that might explain the failure to induce protection in IL-4Ralpha(-/-) mice were detected. However, passive transfer of partial protection to naive IL-4Ralpha(-/-) mice, using serum from vaccinated WT mice, indicates that Th2-associated antibodies such as IgG1 have a role in parasite elimination in BALB/c strain mice and that signaling via IL-4R can be an important factor in the generation of protection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11119510      PMCID: PMC97876          DOI: 10.1128/IAI.69.1.228-236.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  67 in total

1.  IL-12 receptor regulation in IL-12-deficient BALB/c and C57BL/6 mice.

Authors:  F Galbiati; L Rogge; L Adorini
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

2.  Single cell analysis reveals that IL-4 receptor/Stat6 signaling is not required for the in vivo or in vitro development of CD4+ lymphocytes with a Th2 cytokine profile.

Authors:  D Jankovic; M C Kullberg; N Noben-Trauth; P Caspar; W E Paul; A Sher
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

3.  In the absence of IL-12, the induction of Th1-mediated protective immunity by the attenuated schistosome vaccine is impaired, revealing an alternative pathway with Th2-type characteristics.

Authors:  S Anderson; V L Shires; R A Wilson; A P Mountford
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

4.  IL-13 is a susceptibility factor for Leishmania major infection.

Authors:  D J Matthews; C L Emson; G J McKenzie; H E Jolin; J M Blackwell; A N McKenzie
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling.

Authors:  J M Brewer; M Conacher; C A Hunter; M Mohrs; F Brombacher; J Alexander
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

Review 6.  The IL-4 receptor: signaling mechanisms and biologic functions.

Authors:  K Nelms; A D Keegan; J Zamorano; J J Ryan; W E Paul
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

7.  Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling.

Authors:  M Mohrs; B Ledermann; G Köhler; A Dorfmüller; A Gessner; F Brombacher
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

8.  Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile.

Authors:  D Jankovic; M C Kullberg; N Noben-Trauth; P Caspar; J M Ward; A W Cheever; W E Paul; A Sher
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

9.  The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1.

Authors:  D D Donaldson; M J Whitters; L J Fitz; T Y Neben; H Finnerty; S L Henderson; R M O'Hara; D R Beier; K J Turner; C R Wood; M Collins
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

10.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

View more
  25 in total

1.  Ultrastructural changes of adult Schistosoma mansoni worms recovered from C57BL/6 mice passively immunized with normal and vaccinated rabbit sera in vivo.

Authors:  Sherif H Abdeen; Enayat S Reda; Eman A El-Shabasy; Allal Ouhtit
Journal:  Parasitol Res       Date:  2011-05-26       Impact factor: 2.289

2.  Transmission electron microscopic observations on ultrastructural alterations in Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation-attenuated vaccine and/or praziquantel in addition to passive immunization with normal and vaccinated rabbit sera against infection.

Authors:  Eman A El-Shabasy; Enayat S Reda; Sherif H Abdeen; Ashraf E Said; Allal Ouhtit
Journal:  Parasitol Res       Date:  2015-02-18       Impact factor: 2.289

3.  Bartonella henselae-specific cell-mediated immune responses display a predominantly Th1 phenotype in experimentally infected C57BL/6 mice.

Authors:  M Arvand; R Ignatius; T Regnath; H Hahn; M E Mielke
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Structural changes of Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation-attenuated vaccine and/or praziquantel against infection.

Authors:  Enayat S Reda; Allal Ouhtit; Sherif H Abdeen; Eman A El-Shabasy
Journal:  Parasitol Res       Date:  2011-08-09       Impact factor: 2.289

5.  CD40/CD154 interactions are required for the optimal maturation of skin-derived APCs and the induction of helminth-specific IFN-gamma but not IL-4.

Authors:  James P Hewitson; Gavin R Jenkins; Paul A Hamblin; Adrian P Mountford
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

6.  Mice deficient in interleukin-4 (IL-4) or IL-4 receptor alpha have higher resistance to sporozoite infection with Plasmodium berghei (ANKA) than do naive wild-type mice.

Authors:  Michael Saeftel; Andreas Krueger; Sandra Arriens; Volker Heussler; Paul Racz; Bernhard Fleischer; Frank Brombacher; Achim Hoerauf
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

8.  Interleukin-12 p40 secretion by cutaneous CD11c+ and F4/80+ cells is a major feature of the innate immune response in mice that develop Th1-mediated protective immunity to Schistosoma mansoni.

Authors:  Karen G Hogg; Supeecha Kumkate; Sonia Anderson; Adrian P Mountford
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 9.  Granulocytes in helminth infection -- who is calling the shots?

Authors:  B L Makepeace; C Martin; J D Turner; S Specht
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

10.  Fluorescent imaging of antigen released by a skin-invading helminth reveals differential uptake and activation profiles by antigen presenting cells.

Authors:  Ross A Paveley; Sarah A Aynsley; Peter C Cook; Joseph D Turner; Adrian P Mountford
Journal:  PLoS Negl Trop Dis       Date:  2009-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.